To cite this paper use one of the standards below:
EXPRESSION, PURIFICATION AND DETERMINATION OF A SINGLE-DOMAIN ANTIBODY STRUCTURE BY NUCLEAR MAGNETIC RESONANCE
Vanessa Leite
Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro
Now you could share with me your questions, observations and congratulations
Create a topicNanobodies are single domain antibodies (sdAbs) derived from camelid heavy chain
antibody[1,2]. They are characterized by their small size (~12-16 kDa), high stability,
specificity and solubility[1-4]. Therefore, sdAbs are considered non-immunogenics due to their high similarity with variable domain sequences of heavy chains of human antibodies[5]. In this work, the expression of a nanobody (126 amino acids) from camelid – that recognizes the Fc region of IgG in rats, mice and humans – was studied under different conditions (temperature, time, culture media, strain) for determining the better conditions of expression. For the NMR analysis, the cell growth was performed in M9 medium, enriched with 13 C and 15 N, overnight, at 37ºC and using Escherichia coli host and transformation using a pet-25b vector. The protein was purified by immobilized metal affinity chromatography followed by a size-exclusion chromatography. The thermal stability of the sdAb-mrh-IgG was measured using circular dichroism. NMR spectra were acquired for the assignment of the backbone using a 600 MHz spectrometer (Bruker Avance III) with a 5 mm probe at a controlled temperature of 298K.
Lorena Mara Alexandre e Silva
Hello Vanessa. Congratulations on your work and presentation. What protein purity can you achieve with this method? Just cuirous
Elenilson de Godoy Alves Filho
Dear Vanessa, congratulations on your great work!
You divided the experimental section in 8 steps. Which of these steps were developed by you?
Best Regards!
Vanessa Leite
Hi, thank you for the compliment! I did everything described in the work, but always being supervised by someone, as I am an undergrad student and started to work in the beginning of this year (March). So I am still learning everything. Once I learnt the techinique, then I was able of doing (repeating) by myself.
Scott Prosser
Hi Vanessa,
Thanks for your talk! Are the variable domains defined by greater flexibility? Are you planning on deriving new polyclonal nanobodies to disease targets in animals or error prone PCR? And if you were going to design a bivalent Nb where would you insert your fusion protein?
best wishes
Scott Prosser
Vanessa Leite
Hello Scott! About flexibility, we do not know, we want to study it. We do not have plans on working with polyclonal nanobodies, but we have few targets in mind to built a nanobodie against, using in vitro screening. In making a bivalent quimeric protein there is no special reason to chose a fusion at the N- or C-termini of the nanobodie, since they are near in the structure.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper